TATTON: Osimertinib plus savolitinib for patients with EGFR-mutant, MET-amplified NSCLC after progression on EGFR-TKI
TATTON: Osimertinib plus savolitinib for patients with EGFR-mutant, MET-amplified NSCLC after progression on EGFR-TKI
Evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with HPV-associated malignancies
Umbralisib as a monotherapy in patients with relapsed/refractory marginal zone lymphoma
TATTON: Updated results for patients with EGFR-mutant NSCLC
Mesothelin-targeted CAR T-cell therapy safe, shows early promise in patients with advanced solid tumours
HER2-targeted CAR T-cell therapy safe and showing promising antitumour activity in patients with advanced sarcoma
Umbralisib shows early promise for patients with marginal zone lymphoma
KEYNOTE trials show pembrolizumab benefited patients with advanced small cell lung cancer
Gilteritinib improved survival for patients with acute myeloid leukaemia
New developments in soft tissue and bone sarcoma research
Latest updates in melanoma research
Gynaecological cancer: Where are we now?